Developed By: Medical Necessity Criteria Committee
Imaging studies have shown a decrease in activity of the left dorsolateral prefrontal cortex (DLPFC) in depressed patients, and early studies suggested that high frequency (e.g., 5-10 Hz) TMS of the left DLPFC had antidepressant effects. The FDA approved TMS in October 2008 for use in the treatment of treatment-refractory major depressive disorder (TRD) based on the results of a multisite randomized controlled clinical trial.
Scientific literature supports the safety and effectiveness of TMS in treating TRD. It is believed to be generally less effective than Electroconvulsive Therapy (ECT) but with a much more benign side-effect profile. Data do not show an advantage for either rTMS or dTMS compared with the other. A typical course of TMS is 5 days a week for 6 weeks (total of 30 sessions), followed by a 3 week taper of 3 TMS treatments in week 1; 2 TMS treatments the next week, and; 1 TMS treatment in the last week. The role of follow-up or maintenance treatment has not been established in the literature and there is not yet a generally accepted protocol for maintenance treatment. As a result, maintenance TMS is considered by some to be experimental/investigational. Given that TRD is a chronic condition, some patients with a positive response to TMS may benefit from reintroduction or some form of booster sessions. Clinical judgment with consideration of patient history and resources, response to treatment, and appropriateness of other treatments is necessary in order to weigh the appropriateness of additional treatment beyond the acute course.
The Food and Drug Administration (FDA) has approved several transcranial magnetic stimulation (TMS) systems and devices (e.g., NeuroStar® TMS Therapy System (Neuronetics, Inc.), Brainsway Deep TMS System (Brainsway Ltd.), Magstim Rapid2 Therapy System (Magstim Company Limited), MagVita TMS Therapy System (Tonica Elektronik A/S)).
II.
Criteria: CWQI BHC-0014 1. The patient has shown a positive response to treatment as evidenced by a reduction in depressive symptoms on a standardized measurement tool. 2. Additional visits are needed due to a need for re-mapping or other confounding factors. 3. The treatment plan includes a plan for completing treatment with the lowest appropriate number of additional sessions.
C. Reintroduction Criteria:
Authorization for reintroducing TMS after completion of an acute episode of treatment is indicated by ALL of the following:
1. Clinical need for additional treatment is demonstrated by 1 or more of the following: a) Recurrence of symptoms meeting criteria for initial authorization of TMS; or b) Patient history demonstrating a substantial risk of deterioration that can't be prevented by other means such as pharmacological and/or psychotherapeutic intervention. 2. A reasonable expectation that additional treatment will produce clinical benefit 3. Other treatment approaches (e.g., psychotherapy, pharmacotherapy) are employed concurrently as appropriate; AND 4. Treatment is provided at the lowest number of sessions required to maintain/continue improvement.
III. Information Submitted with the Prior Authorization Request:
Psychiatric evaluation including diagnosis, symptomatology, results of standardized evidence based depression rating scale, treatment history (psychotherapeutic and pharmacologic), screening for contraindications and requested services.
IV. CPT or HCPC codes covered:
Codes Description 
